azd1163
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2023 (NCT06103877)
Timeline
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07276581 | Phase 2 | Dec 15, 2025 | AstraZeneca |
| NCT06103877 | Phase 1 | Oct 31, 2023 | AstraZeneca, Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2023 |
| Parexel | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1